Cartesian Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.8M-92.8% YoYTTM through 30 Jun 2026
Net Income -$130.3MTTM through 30 Jun 2026
Free Cash Flow -$78.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -5,127.1% |
| Net Margin | -4,658.6% |
Returns
103.2%ROE
-44.0%ROA
Balance Sheet Health
Debt / Equity-0.10x
Current Ratio8.65x
Net Debt-$112.5Mnet cash position
Cash & Equivalents$147.6M
Quality Metrics
Altman Z-Score-4.36
Piotroski F-Score1 / 9
FCF Margin-2,810.6%
Rule of 40-2,890.8
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $2.8M
Diluted EPS-$5.78TTMFY2025: $-5.02
Dividend
No dividend
Capital Allocation
R&D Spend$68.4M
Capex Intensity74.5%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.